AI Limitations in Drug Research Spark Scrutiny of Big Pharma Spending
What happened
A recent report noted that the widespread belief that AI large language models could reason like humans led to massive spending across various applications, some of which were speculative. This realization about the limitations of AI models—which are fundamentally computer code—is now being observed in the field of Big Pharma drug development.
From healthimpactnews.com
Why it matters
The realization that current AI models may not possess human-level reasoning capabilities could impact the viability of large-scale AI-driven drug research projects. This shift in understanding may affect the competitive position and market prices of pharmaceutical companies relying heavily on this technology.
From healthimpactnews.com
Who's involved
- MicrosoftAmerican multinational technology corporation involved in the AI race
- American Heart AssociationUS nonprofit funding cardiovascular medical research
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CRISPR TherapeuticsSpeculative
CRISPR Therapeutics might face a shift in competitive position or market prices due to the failure of AI in drug development.
- NovartisSpeculative
Novartis might face a shift in competitive position or market prices due to the failure of AI in drug development.
Keep exploring
The entities involved
-
Microsoft
American multinational technology corporation
-
American Heart Association
US nonprofit funding cardiovascular medical research, educating consumers on healthy living, and fostering cardiac care
Related events
- Big Tech firms plan to invest over $700 billion in AI infrastructure, with healthcare identified as a key test case for AI returns.
- AI spending drives corporate investment while war interrupts oil shipping, causing inflation risk.
- Goldman Sachs projects that major tech companies, including Meta, Microsoft, Amazon, and Oracle, are fueling the AI boom through massive global AI-linked bond issuance.